1. Preliminary study on the diagnostic value of LEAP-2 and CK18 in biopsy-proven MAFLD
- Author
-
Zhi Liu, Qiao Ren, Hongying Mu, Yuping Zeng, Zhenmei An, and He He
- Subjects
CK18 ,M30 ,M65 ,LEAP-2 ,MAFLD ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) has become the leading cause of chronic liver disease. Liver biopsy, as the diagnostic gold standard, is invasive and has sampling bias, making it particularly important to search for sensitive and specific biomarkers for diagnosis. Cytokeratin 18 (CK18) M30 and M65 are products of liver cell apoptosis and necrosis, respectively, and liver-expressed antimicrobial peptide 2 (LEAP-2) is a related indicator of glucose and lipid metabolism. Correlation studies have found that all three indicators positively correlate with the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Through comparison of diagnostic values, it was found that CK18 M65 can better distinguish between healthy individuals and MAFLD; LEAP-2 can effectively distinguish MAFLD from other liver diseases, especially ALD.
- Published
- 2024
- Full Text
- View/download PDF